Literature DB >> 18650033

Comparison of expired carbon monoxide and plasma cotinine as markers of cigarette abstinence.

Peter Jatlow1, Benjamin A Toll, Vanessa Leary, Suchitra Krishnan-Sarin, Stephanie S O'Malley.   

Abstract

The clinical pharmacology of biochemical measures of nicotine exposure has been thoroughly reviewed with regard to usefulness and limitations in detecting abstinence from cigarette smoking. While plasma nicotine concentration measures only acute nicotine exposure, plasma, salivary, and urine cotinine concentrations reflect exposure over an extended period of time. Although, expired carbon monoxide (CO) is frequently used to confirm self reports, it has a relatively short half life, calling into question whether this measure might provide misleading information by exaggerating smoking cessation success rates. To examine this question, we analyzed expired CO, plasma cotinine and self report data collected in a clinical trial in which subjects (N=207) were randomly assigned to gain- or loss-framed messages for smoking cessation in combination with open label sustained-release bupropion (300 mg/day). In examining measurements collected at 6 weeks, 3 and 6 months, results showed that CO significantly overestimated abstinence rates as compared with cotinine, although the discrepancy was less at the later time points. These data suggest that while expired CO is a useful and well-established marker in certain contexts, when testing extended abstinence from smoking with non-nicotine medications, cotinine measurements should be preferred.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18650033      PMCID: PMC2577604          DOI: 10.1016/j.drugalcdep.2008.05.013

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  35 in total

1.  Are higher doses of nicotine replacement more effective for smoking cessation?

Authors:  J R Hughes; G R Lesmes; D K Hatsukami; R L Richmond; E Lichtenstein; D E Jorenby; J O Broughton; S P Fortmann; S J Leischow; J P McKenna; S I Rennard; W C Wadland; S A Heatley
Journal:  Nicotine Tob Res       Date:  1999-06       Impact factor: 4.244

2.  Efficacy of a nicotine lozenge for smoking cessation.

Authors:  Saul Shiffman; Carolyn M Dresler; Peter Hajek; Simon J A Gilburt; Darren A Targett; Kenneth R Strahs
Journal:  Arch Intern Med       Date:  2002-06-10

3.  Biochemical verification of tobacco use and cessation.

Authors: 
Journal:  Nicotine Tob Res       Date:  2002-05       Impact factor: 4.244

4.  Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials.

Authors:  J T Hays; I T Croghan; D R Schroeder; K P Offord; R D Hurt; T D Wolter; M A Nides; M Davidson
Journal:  Am J Public Health       Date:  1999-11       Impact factor: 9.308

5.  Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study.

Authors:  D H Gonzales; M A Nides; L H Ferry; R P Kustra; B D Jamerson; N Segall; L A Herrero; A Krishen; A Sweeney; K Buaron; A Metz
Journal:  Clin Pharmacol Ther       Date:  2001-06       Impact factor: 6.875

6.  Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial.

Authors:  D Tashkin; R Kanner; W Bailey; S Buist; P Anderson; M Nides; D Gonzales; G Dozier; M K Patel; B Jamerson
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

7.  A high-performance liquid-chromatographic method for routine simultaneous determination of nicotine and cotinine in plasma.

Authors:  M Hariharan; T VanNoord; J F Greden
Journal:  Clin Chem       Date:  1988-04       Impact factor: 8.327

8.  Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.

Authors:  J T Hays; R D Hurt; N A Rigotti; R Niaura; D Gonzales; M J Durcan; D P Sachs; T D Wolter; A S Buist; J A Johnston; J D White
Journal:  Ann Intern Med       Date:  2001-09-18       Impact factor: 25.391

9.  Detecting smoking following smoking cessation treatment.

Authors:  Peter Gariti; Arthur I Alterman; Ronald Ehrman; Francis D Mulvaney; Charles P O'Brien
Journal:  Drug Alcohol Depend       Date:  2002-01-01       Impact factor: 4.492

10.  Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial.

Authors:  Jasjit S Ahluwalia; Kari Jo Harris; Delwyn Catley; Kolawole S Okuyemi; Matthew S Mayo
Journal:  JAMA       Date:  2002 Jul 24-31       Impact factor: 56.272

View more
  26 in total

1.  Breath carbon monoxide and semiquantitative saliva cotinine as biomarkers for smoking.

Authors:  Gina F Marrone; Mane Paulpillai; Rebecca J Evans; Edward G Singleton; Stephen J Heishman
Journal:  Hum Psychopharmacol       Date:  2010-01       Impact factor: 1.672

2.  Accuracy and utility of an epigenetic biomarker for smoking in populations with varying rates of false self-report.

Authors:  Allan M Andersen; Robert A Philibert; Fredrick X Gibbons; Ronald L Simons; Jeffrey Long
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-06-14       Impact factor: 3.568

3.  Application of the protection motivation theory in predicting cigarette smoking among adolescents in China.

Authors:  Yaqiong Yan; Angela J Jacques-Tiura; Xinguang Chen; Nianhua Xie; Jing Chen; Niannian Yang; Jie Gong; Karen Kolmodin Macdonell
Journal:  Addict Behav       Date:  2013-10-02       Impact factor: 3.913

4.  Bupropion SR and contingency management for adolescent smoking cessation.

Authors:  Kevin M Gray; Matthew J Carpenter; Nathaniel L Baker; Karen J Hartwell; A Lee Lewis; D Walter Hiott; Deborah Deas; Himanshu P Upadhyaya
Journal:  J Subst Abuse Treat       Date:  2010-10-08

5.  Sequential combination of self-report, breath carbon monoxide, and saliva cotinine to assess smoking status.

Authors:  M A Javors; J P Hatch; R J Lamb
Journal:  Drug Alcohol Depend       Date:  2010-09-06       Impact factor: 4.492

6.  Using breath carbon monoxide to validate self-reported tobacco smoking in remote Australian Indigenous communities.

Authors:  David J Maclaren; Katherine M Conigrave; Jan A Robertson; Rowena G Ivers; Sandra Eades; Alan R Clough
Journal:  Popul Health Metr       Date:  2010-02-20

7.  A Role for Epigenetics in Broadening the Scope of Pediatric Care in the Prevention of Adolescent Smoking.

Authors:  Steven R H Beach; Meg Gerrard; Frederick X Gibbons; Gene H Brody; Robert A Philibert
Journal:  Epigenet Diagn Ther       Date:  2015

8.  Acceptability of an Internet-based contingency management intervention for smoking cessation: views of smokers, nonsmokers, and healthcare professionals.

Authors:  Bethany R Raiff; Brantley P Jarvis; Marissa Turturici; Jesse Dallery
Journal:  Exp Clin Psychopharmacol       Date:  2013-06       Impact factor: 3.157

9.  A brief 7-day estimate of alcohol consumption for use in smoking cessation clinical trials.

Authors:  Benjamin A Toll; Robert F Leeman; Sherry A McKee; Stephanie S O'Malley
Journal:  Addict Behav       Date:  2008-07-23       Impact factor: 3.913

10.  Assessing tobacco use in an African population: Serum and urine cotinine cut-offs from South Africa.

Authors:  Lisa J Ware; Karen Charlton; Ruan Kruger; Yolandi Breet; Johannes van Rooyen; Hugo Huisman; Shani Botha; Aletta S Uys; Kirsten L Rennie; Nirmala Naidoo; Paul Kowal; Aletta E Schutte
Journal:  Drug Alcohol Depend       Date:  2018-12-21       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.